EVOK Stock UPDATES Evoke Pharma Inc (EVOK) 6.80 08/02/2014 1

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2014 at 2:24 PM

Evoke Pharma Inc (EVOK) 6.80 $EVOK

Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13, 2014, after the close of the market.

Nasdaq stocks posting largest percentage decreases
AP - Tue Jul 01, 12:22PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

Evoke Pharma signs USD4.5m loan facility with Square 1 Bank
M2 - Thu May 29, 3:49AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) revealed on Wednesday the execution of USD4.5m term loan deal to support its general corporate purposes, working capital purposes and capital expenditures with Square 1 Bank (NasdaqGS:SQBK).

Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank
GlobeNewswire - Wed May 28, 3:09PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has secured a $4.5 million term loan agreement with Square 1 Bank (Nasdaq:SQBK). In advance of this transaction, Evoke repaid the remaining balance of its loan with Silicon Valley Bank of $2.4 million. The facility will support general corporate and working capital purposes and capital expenditures.

Evoke Pharma Reports Fourth Quarter and Year End 2013 Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.

Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014, after the close of the market.

Evoke Pharma to Present at 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.

Diabetic Gastroparesis - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/7ctztm/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H1 2014" report to their offering. 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Scope - A snapshot of the global therapeutic scenario for Diabetic Gastroparesis. - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Diabetic Gastroparesis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles metoclopramide hydrochloride - Drug Profile RM-131 - Drug Profile velusetrag - Drug Profile Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile TC-6499 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Theravance, Inc. Evoke Pharma, Inc. Targacept, Inc. Cempra, Inc. Rhythm Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7ctztm/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics
GlobeNewswire - Wed Jan 22, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide.

Diabetic Gastroparesis Global Clinical Trials Review, H2 2013 Report Available Now
M2 - Mon Jan 13, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/kd5vzq/diabetic) has announced the addition of the "Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Diabetic Gastroparesis Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Gastroparesis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Gastroparesis. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Axcan Pharma, Inc. - Duke University - Evoke Pharma, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Goteborg University - Malmo University Hospital - Novartis AG - Osaka City University - Questcor Pharmaceuticals, Inc. - Rabin Medical Center - Rhythm Pharmaceuticals - Shaare Zedek Medical Center - Targacept, Inc. - Theravance, Inc. - Tranzyme Pharma, Inc. - Vienna General Hospital - Yokohama City University For more information visit http://www.researchandmarkets.com/research/kd5vzq/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Evoke Pharma to Present at Biotech Showcase(TM) 2014
GlobeNewswire - Tue Jan 07, 7:31AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer is scheduled to present at Biotech Showcase(TM) 2014, being held January 13-15, 2014 in San Francisco, Calif.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...